You are here
FDA, Lilly Issue Warnings About Duloxetine
August 3, 2015
October 19, 2005 -- ROCKVILLE, MD -- Eli Lilly and FDA notified healthcare professionals of revision to the PRECAUTIONS/Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain. Postmarketing reports of hepatic injury (including hepatitis and cholestatic jaundice) suggest that patients with preexisting liver disease who take duloxetine may have an increased risk for further liver damage. The new labeling extends the Precaution against using Cymbalta in patients with substantial alcohol use to include those patients with chronic liver disease. It is recommended that Cymbalta not be administered to patients with any hepatic insufficiency.
To view the health care letter click here: Letter
To view the label click here: Label
Source: The Food and Drug Administration
Discovery seen as possibly leading to new anti-TB drugs
Study points to permanent hair dye and straighteners
Safety concerns include liver injury and interactions with other drugs
DisposeRx helps with compliance
No tobacco product is safe, says the lung heath group
No more digital rectal exams?
How malaria parasites evade first-line drugs
A new way to fight staph infections
Score could help prevent misuse among cancer patients